Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Alector Inc (ALEC)

Alector Inc (ALEC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,908,650
  • Shares Outstanding, K 80,875
  • Annual Sales, $ 21,100 K
  • Annual Income, $ -190,230 K
  • 60-Month Beta 1.06
  • Price/Sales 93.00
  • Price/Cash Flow N/A
  • Price/Book 11.68
Trade ALEC with:

Options Overview Details

View History
  • Implied Volatility 71.81%
  • Historical Volatility 90.40%
  • IV Percentile 8%
  • IV Rank 4.24%
  • IV High 219.76% on 11/10/20
  • IV Low 65.25% on 08/27/21
  • Put/Call Vol Ratio 0.12
  • Today's Volume 92
  • Volume Avg (30-Day) 461
  • Put/Call OI Ratio 1.01
  • Today's Open Interest 2,393
  • Open Int (30-Day) 3,029

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.50
  • Number of Estimates 3
  • High Estimate -0.31
  • Low Estimate -0.65
  • Prior Year -0.67
  • Growth Rate Est. (year over year) +25.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.04 +12.17%
on 09/09/21
29.30 -19.45%
on 09/02/21
-2.83 (-10.71%)
since 08/24/21
3-Month
20.37 +15.86%
on 06/30/21
43.32 -45.52%
on 07/02/21
+2.60 (+12.38%)
since 06/24/21
52-Week
9.12 +158.77%
on 10/30/20
43.32 -45.52%
on 07/02/21
+12.42 (+111.09%)
since 09/24/20

Most Recent Stories

More News
Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL001 in Amyotrophic Lateral Sclerosis (ALS)

Randomized, placebo-controlled Phase 2 trial will enroll patients with C9orf72-associated ALS

ALEC : 23.60 (-2.72%)
Alector Provides Executive Leadership Update

Planned Transitions Announced for Shehnaaz Suliman, M.D., MBA, MPhil, President and Chief Operating Officer and Robert Paul, M.D., Ph.D., Chief Medical Officer

ALEC : 23.60 (-2.72%)
Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of 0.00% and -26.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ALEC : 23.60 (-2.72%)
Alector: Q2 Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ Alector Inc. (ALEC) on Tuesday reported a loss of $55.1 million in its second quarter.

ALEC : 23.60 (-2.72%)
Alector Reports Second Quarter 2021 Financial Results

Presented twelve-month data from ongoing AL001 open-label Phase 2 study in FTD-GRN at the 2021 Alzheimer's Association International Conference (AAIC)

ALEC : 23.60 (-2.72%)
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALEC : 23.60 (-2.72%)
Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation

AL001 Successfully Restored Progranulin to Normal Levels in FTD-GRN Patients

ALEC : 23.60 (-2.72%)
Alector to Present New Data from Frontotemporal Dementia and Alzheimer's Disease Programs at the 2021 Alzheimer's Association International Conference

Oral Presentation to Highlight Data from the Ongoing Phase 2 Study of AL001 in FTD-GRN

ALEC : 23.60 (-2.72%)
Alector's (ALEC) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Alector, Inc. (ALEC).

ALEC : 23.60 (-2.72%)
Pharma Stock Roundup: GSK's New Deal With Alector, MRK & AZN's FDA Updates

Glaxo (GSK) to co-develop Alector's two candidates for neurodegenerative diseases. FDA updates for Merck (MRK) and AstraZeneca (AZN)

AZN : 60.35 (+1.46%)
GSK : 38.39 (-2.41%)
MRK : 73.61 (+0.77%)
LLY : 231.68 (-0.22%)
AMGN : 213.61 (-0.67%)
ALEC : 23.60 (-2.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Alector Inc. is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Its product portfolio includes AL001, AL101, Al002 and AL003 which are in clinical stage. Alector Inc. is headquartered in South San Francisco,...

See More

Key Turning Points

3rd Resistance Point 25.40
2nd Resistance Point 24.94
1st Resistance Point 24.27
Last Price 23.60
1st Support Level 23.13
2nd Support Level 22.67
3rd Support Level 22.00

See More

52-Week High 43.32
Fibonacci 61.8% 30.26
Fibonacci 50% 26.22
Last Price 23.60
Fibonacci 38.2% 22.18
52-Week Low 9.12

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar